Nuclear Medicine

Nuclear medicine (also called molecular imaging) includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. Nuclear imaging is achieved by injecting small amounts of radioactive material (radiopharmaceuticals) into patients before or during their scan. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

mergers and acquisitions M&A puzzle

GE HealthCare acquires full stake in radiopharma firm that generated $183M last year

Tokyo-based Nihon Medi-Physics' portfolio includes nuclear imaging agents delivered across oncology, neurology and cardiology. 

weight loss scale overweight obese lose weight pounds

Radiologists say hidden fat can predict Alzheimer’s 20 years before symptoms arise

Higher levels of visceral fat were linked to increased amyloid, according to new research being presented this week at RSNA 2024 in Chicago. 

Telix Pharmaceuticals

Radiopharmaceutical firm Telix investing up to $171M to acquire portfolio of imaging agents

The Australian company will secure exclusive worldwide rights to a suite of diagnostic and therapeutic candidates geared toward urological cancers. 

Lantheus

Lantheus expects sales of ‘blockbuster’ cancer imaging agent to surpass $1B in 2024

Pylarify is a PSMA-targeted PET agent for pinpointing suspected metastasis or recurrence of prostate cancer, which will be impacted by a new Medicare policy change.  

Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Thumbnail

Bracco Imaging radiopharmaceutical firm Blue Earth Therapeutics raises nearly $77M

Leaders said the funding will help Blue Earth to further advance its development of PSMA-targeted therapies for prostate cancer. 

GE HealthCare Omni Legend PET/CT scanner production North America United States

GE HealthCare moves PET/CT scanner production to United States

The all-in-one Omni Legend PET/CT scanner is now being manufactured in a new production facility in Waukesha, Wisconsin.

FDA grants priority review for new brain cancer imaging agent

Pixclara (18F-FET) is a positron emission tomography product for the characterization of progressive or recurrent gliomas. 

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The all-in-one Omni Legend PET/CT scanner is now being manufactured in a new production facility in Waukesha, Wisconsin.